Skip to main content
Premium Trial:

Request an Annual Quote

Agilent Buys Automated Lab Technologies Company Velocity11

NEW YORK (GenomeWeb News) – Agilent Technologies said yesterday that it has inked a deal to buy Velocity11, a private life science lab technology company, for an undisclosed sum.
Agilent believes the acquisition will strengthen its automated sample-preparation offerings across a broad range of applications.
Velocity11 designs, makes, and markets robotic solutions including stand-alone, bench-top, and multi-armed robotic systems. The company also markets software designed to control the robotics in its products.
Agilent said it would offer jobs to “substantially all of Velicity11’s approximately 150 employees worldwide.”
Velocity11 is based in Menlo Park, Calif., with a second office in Melbourn, Hertfordshire, UK, and has field sales and support “throughout the US and Western Europe.”
Nick Roelofs, Agilent's VP of life science systems and solutions, said the acquisition will help the firm offer automated solutions that can “speed drug discovery and genetic research.”
Financial terms of the agreement were not released.

The Scan

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.

Using Bees to Gain Insights into Urban Microbiomes

As bees buzz around, they pick up debris that provides insight into the metagenome of their surroundings, researchers report in Environmental Microbiome.

Age, Genetic Risk Tied to Blood Lipid Changes in New Study

A study appearing in JAMA Network Open suggests strategies to address high lipid levels should focus on individuals with high genetic risk and at specific ages.

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.